RHS
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
RHS Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
RHS Limited
📈 Performance
Price History
-100.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RHS
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RHS
N/A
RHS investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in RHS also invest in...
Want more shares? Try these...
Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. Its portfolio includes Core Lab and artificial intelligence (AI)-powered products to partner with clinicians and radiologists for diagnosis, and management of patients. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. Its other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart. The company operates as the Clinical Trial Research Organisation (CRO) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound.
🙌 Performance (5Yr p.a)
-12.00%
📊 Share price
$0.06 AUD
🩺 HEALTH CARE
